A pre-clinical trial of opaganib from Israel’s Redhill (see here previously) shows that its strong antiviral and anti-inflammatory activities can inhibit any variant of the SARS-Cov-2 virus. Opaganib targets SK2 – a key enzyme used by the virus to replicate, irrespective of spike protein mutations.
Protection against Delta variant
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.